Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119533 | 0.90 | GPR119 (0.50) | GPR119USP30PTPN2PTPN1PTPN6 | |
| SCHEMBL5111724 | 0.88 | GPR119 (0.48) | GPR119USP30KDM1AKITGBA1 | |
| SCHEMBL3168609 | 0.87 | GPR119 (0.42) | GPR119USP30KDM1AKITGBA1 | |
| SCHEMBL3173885 | 0.87 | GPR119 (0.42) | GPR119USP30KDM1AKITGBA1 | |
| SCHEMBL3168603 | 0.87 | GPR119 (0.42) | GPR119USP30KDM1AKITGBA1 | |
| SCHEMBL3993291 | 0.82 | CYP11B1 (0.38) | GPR119USP30KDM1ACYP11B1CYP11B2 | |
| SCHEMBL5112850 | 0.81 | MEN1 (0.46) | GPR119USP30 | |
| SCHEMBL5120216 | 0.81 | USP30 (0.41) | GPR119USP30PTPN2PTPN1PTPN6 | |
| SCHEMBL5114970 | 0.80 | TGFBR1 (0.44) | GPR119USP30PTPN2PTPN1PTPN6 | |
| SCHEMBL4517473 | 0.79 | GPR119 (0.50) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| EP-1846400-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006074388-A2 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148823-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148823-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | GPR119 540/4885USP30 1952/4885KDM1A 1934/4885 |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | GPR119 540/4885USP30 1952/4885KDM1A 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.